Allena Pharmaceuticals, Inc. Dividends Paid (Common)

Dividends Paid (Common) of ALNA for past 10 years: annual, quarterly and twelve month trailing (TTM) including Dividends Paid (Common) growth rates and interactive chart.


Highlights and Quick Summary

  • Dividends Paid (Common) for the quarter ending March 31, 2022 was $0 (a NaN% decrease compared to previous quarter)
  • Year-over-year quarterly Dividends Paid (Common) decreased by NaN%
  • Annual Dividends Paid (Common) for 2021 was $0 (a NaN% decrease from previous year)
  • Annual Dividends Paid (Common) for 2020 was $0 (a NaN% decrease from previous year)
  • Annual Dividends Paid (Common) for 2019 was $0 (a NaN% decrease from previous year)
  • Twelve month Dividends Paid (Common) ending March 31, 2022 was $0 (a NaN% decrease compared to previous quarter)
  • Twelve month trailing Dividends Paid (Common) decreased by NaN% year-over-year
Trailing Dividends Paid (Common) for the last four month:
31 Mar '22 31 Dec '21 30 Sep '21 30 Jun '21
$0 $0 $0 $0
Visit stockrow.com/ALNA for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Dividends Paid (Common) of Allena Pharmaceuticals, Inc.

Most recent Dividends Paid (Common)of ALNA including historical data for past 10 years.

Interactive Chart of Dividends Paid (Common) of Allena Pharmaceuticals, Inc.

Allena Pharmaceuticals, Inc. Dividends Paid (Common) for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2022 $0.0
2021 $0.0 $0.0 $0.0 $0.0 $0.0
2020 $0.0 $0.0 $0.0 $0.0 $0.0
2019 $0.0 $0.0 $0.0 $0.0 $0.0
2018 $0.0 $0.0 $0.0 $0.0 $0.0
2017 $0.0 $0.0 $0.0 $0.0 $0.0
2016 $0.0 $0.0 $0.0
2015 $0.0 $0.0

Business Profile of Allena Pharmaceuticals, Inc.

Sector: Healthcare
Industry: Biotechnology
Allena Pharmaceuticals, Inc., a biopharmaceutical company, discovers, develops, and commercializes oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. Its lead product candidate is ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and gout in the setting of advanced chronic kidney disease. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.